Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation.
about
Encephalomyocarditis virus 2A protein is required for viral pathogenesis and inhibition of apoptosisA novel cellular protein, VPEF, facilitates vaccinia virus penetration into HeLa cells through fluid phase endocytosis.A method for the generation of ectromelia virus (ECTV) recombinants: in vivo analysis of ECTV vCD30 deletion mutants.Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R.Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors.Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.Epitope mapping by random peptide phage display reveals essential residues for vaccinia extracellular enveloped virion spread.Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.Smallpox vaccines: targets of protective immunity.Smallpox and live-virus vaccination in transplant recipients.Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organsDevelopment of ST-246® for Treatment of Poxvirus Infections.Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice.Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6Resistance of a vaccinia virus A34R deletion mutant to spontaneous rupture of the outer membrane of progeny virions on the surface of infected cellsInhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein.Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis.Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope.Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challengeUnusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine.Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastasesVaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccinationA rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complementVaccinia virus, a promising new therapeutic agent for pancreatic cancer.Vaccinia virus induces programmed necrosis in ovarian cancer cellsHeavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5.Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.Combined cytolytic effects of a vaccinia virus encoding a single chain trimer of MHC-I with a Tax-epitope and Tax-specific CTLs on HTLV-I-infected cells in a rat model.An intravenous stimulus package for oncolytic virotherapy.The extracellular domain of vaccinia virus protein B5R affects plaque phenotype, extracellular enveloped virus release, and intracellular actin tail formation.Oncolytic Viral Therapy for Mesothelioma.Characterization and use of mammalian-expressed vaccinia virus extracellular membrane proteins for quantification of the humoral immune response to smallpox vaccines.Studies in smallpox and vaccination. 1913.Modulation of the Tumor Microenvironment by CXCR4 Antagonist-Armed Viral Oncotherapy Enhances the Antitumor Efficacy of Dendritic Cell Vaccines against Neuroblastoma in Syngeneic Mice
P2860
Q28744244-77AB87AC-0B2D-416B-A2ED-042CC4B1A7CFQ30483178-01605C9C-4BFB-4D7F-980C-DB1575DB018BQ33429965-864B5B1D-C755-4BD9-9D55-ABF1480CC30CQ33780553-69F6551A-B4FC-4C71-8939-33B7B1AFDBE1Q33936717-5DC4812C-2ACF-4B3A-B351-8AE6EA1DF2C4Q34212910-7EFB33FB-372F-403D-923A-C7720EB3023FQ34420319-E064658B-1948-4A9F-8499-443105055405Q34502253-3F60FAB6-A1D5-4BCD-B673-206772D98544Q34780607-BCBCC576-9879-4AF2-A0EB-5C7D8067FD32Q35157553-C0F3A42F-0F7C-4670-BEE9-62B671993421Q35192889-70FCFB65-34DD-4F89-97E1-1B49B61FC1F2Q35260385-D525AF94-8B80-487C-B2BB-308B3CB996ABQ35339702-B9BCC92F-F66D-475E-BCBD-727C8C6F07EDQ35623101-5C8EC340-AF92-4387-9BD2-56344FB469D8Q35947572-7BD5025C-B274-442B-B8FA-47F0BE0849FBQ36103310-132AD222-57D1-4E7E-B25A-74CCEE1EC8D6Q36414333-001F560E-6F01-470B-B2C6-9BA5507CD7CBQ36483436-9F76CCBF-F191-4286-834C-3B50103B9660Q36496450-292C9B0D-8E77-48BD-916C-62C3788885FAQ36498244-1BD57443-F5D7-449A-A953-653EA41D311CQ36559797-3CC2D154-98AD-4B92-9699-80E07B193129Q36659289-0C0CBF12-0C0C-4B63-A0FB-88CD48037711Q36747524-761739F4-E23D-4C9D-B116-113F391CDF9FQ36797094-9F2B333C-E6F9-41B8-9D58-49F6B247DAF7Q36883833-8FBCD1AF-B116-4DB0-9CB7-965CC025BD5AQ37051617-B6D4F386-A7F5-4E2C-B695-098FE48FEFF2Q37158473-6AABF230-5F38-41C9-8285-314E035C763BQ37316876-208030BE-187D-4005-B02D-E8CB4DE44FF4Q37452067-4B5C3FBB-F3C5-4070-B410-C81B3604F741Q37511609-38E08B1E-D3D2-47CC-8017-DE25E724FDDEQ37700567-FD2FEEB2-5C88-4359-8016-C372D06BD7B6Q39319601-C9686EF8-579A-4772-9087-9FAD9340503AQ39577986-D97EF8B5-328F-4DB1-9532-A69820AEC2F2Q40051845-9E4A2634-63B5-4946-8AB5-DB62E77E9A13Q42633733-28BC7966-F913-403A-9A58-C0485A237850Q48718137-70610457-317C-4593-8F47-B71D2EFF19D0Q58701885-A846B0EB-147B-4664-8796-A722CEE37E08
P2860
Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Antibodies against vaccinia vi ...... ted cells and comet formation.
@en
type
label
Antibodies against vaccinia vi ...... ted cells and comet formation.
@en
prefLabel
Antibodies against vaccinia vi ...... ted cells and comet formation.
@en
P2093
P1476
Antibodies against vaccinia vi ...... ted cells and comet formation.
@en
P2093
Hollinshead M
Vanderplasschen A
P304
P356
10.1099/0022-1317-78-8-2041
P407
P478
78 ( Pt 8)
P577
1997-08-01T00:00:00Z